Literature DB >> 27162473

Sonidegib (Odomzo) for the Systemic Treatment of Adults With Recurrent, Locally Advanced Basal Cell Skin Cancer.

Troy Kish, Lauren Corry.   

Abstract

Entities:  

Year:  2016        PMID： 27162473      PMCID： PMC4849341     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  10 in total

Review 1.  Platinum-based cytotoxic therapy in basal cell carcinoma--a review of the literature.

Authors:  K Moeholt; H Aagaard; P Pfeiffer; O Hansen
Journal:  Acta Oncol       Date:  1996       Impact factor: 4.089

Review 2.  Hedgehog: functions and mechanisms.

Authors:  Markku Varjosalo; Jussi Taipale
Journal:  Genes Dev       Date:  2008-09-15       Impact factor: 11.361

3.  Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012.

Authors:  Howard W Rogers; Martin A Weinstock; Steven R Feldman; Brett M Coldiron
Journal:  JAMA Dermatol       Date:  2015-10       Impact factor: 10.282

4.  Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011.

Authors:  Gery P Guy; Steven R Machlin; Donatus U Ekwueme; K Robin Yabroff
Journal:  Am J Prev Med       Date:  2014-11-10       Impact factor: 5.043

5.  Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.

Authors:  Michael R Migden; Alexander Guminski; Ralf Gutzmer; Luc Dirix; Karl D Lewis; Patrick Combemale; Robert M Herd; Ragini Kudchadkar; Uwe Trefzer; Sven Gogov; Celine Pallaud; Tingting Yi; Manisha Mone; Martin Kaatz; Carmen Loquai; Alexander J Stratigos; Hans-Joachim Schulze; Ruth Plummer; Anne Lynn S Chang; Frank Cornélis; John T Lear; Dalila Sellami; Reinhard Dummer
Journal:  Lancet Oncol       Date:  2015-05-14       Impact factor: 41.316

6.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

Authors:  Aleksandar Sekulic; Michael R Migden; Anthony E Oro; Luc Dirix; Karl D Lewis; John D Hainsworth; James A Solomon; Simon Yoo; Sarah T Arron; Philip A Friedlander; Ellen Marmur; Charles M Rudin; Anne Lynn S Chang; Jennifer A Low; Howard M Mackey; Robert L Yauch; Richard A Graham; Josina C Reddy; Axel Hauschild
Journal:  N Engl J Med       Date:  2012-06-07       Impact factor: 91.245

7.  A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.

Authors:  Jordi Rodon; Hussein A Tawbi; Anne L Thomas; Ronald G Stoller; Christian P Turtschi; Jose Baselga; John Sarantopoulos; Devalingam Mahalingam; Yaping Shou; Melissa A Moles; Lin Yang; Camille Granvil; Eunju Hurh; Kristine L Rose; Dereck D Amakye; Reinhard Dummer; Alain C Mita
Journal:  Clin Cancer Res       Date:  2014-02-12       Impact factor: 12.531

8.  Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature.

Authors:  H von Domarus; P J Stevens
Journal:  J Am Acad Dermatol       Date:  1984-06       Impact factor: 11.527

Review 9.  Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations.

Authors:  Shalini V Mohan; Anne Lynn S Chang
Journal:  Curr Dermatol Rep       Date:  2014-02-09

Review 10.  Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors.

Authors:  Leslie A Fecher; William H Sharfman
Journal:  Biologics       Date:  2015-11-06
  10 in total
  6 in total

Review 1.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

2.  Synthesis and Investigation of S-Substituted 2-Mercaptobenzoimidazoles as Inhibitors of Hedgehog Signaling.

Authors:  Simone Gräßle; Steven Susanto; Sonja Sievers; Emel Tavsan; Martin Nieger; Nicole Jung; Stefan Bräse
Journal:  ACS Med Chem Lett       Date:  2017-07-28       Impact factor: 4.345

3.  Aging and the treatment of basal cell carcinoma.

Authors:  Shreya Sreekantaswamy; Justin Endo; Amy Chen; Daniel Butler; Lily Morrison; Eleni Linos
Journal:  Clin Dermatol       Date:  2019-06-16       Impact factor: 3.541

Review 4.  Differential pharmacology and clinical utility of sonidegib in advanced basal cell carcinoma.

Authors:  Mohd Wahid; Arshad Jawed; Sajad Ahmad Dar; Raju K Mandal; Shafiul Haque
Journal:  Onco Targets Ther       Date:  2017-01-24       Impact factor: 4.147

Review 5.  Understanding the Molecular Genetics of Basal Cell Carcinoma.

Authors:  Cristina Pellegrini; Maria Giovanna Maturo; Lucia Di Nardo; Valeria Ciciarelli; Carlota Gutiérrez García-Rodrigo; Maria Concetta Fargnoli
Journal:  Int J Mol Sci       Date:  2017-11-22       Impact factor: 5.923

6.  Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.

Authors:  Jorge E Cortes; Florian H Heidel; Andrzej Hellmann; Walter Fiedler; B Douglas Smith; Tadeusz Robak; Pau Montesinos; Daniel A Pollyea; Pierre DesJardins; Oliver Ottmann; Weidong Wendy Ma; M Naveed Shaik; A Douglas Laird; Mirjana Zeremski; Ashleigh O'Connell; Geoffrey Chan; Michael Heuser
Journal:  Leukemia       Date:  2018-12-16       Impact factor: 11.528
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.